The anticancer effects of HDAC inhibitors require the immune system.
Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.
Cancer Therapeutics Program; The Peter MacCallum Cancer Centre; East Melbourne, VIC Australia ; Cancer Immunology Programs; The Peter MacCallum Cancer Centre; East Melbourne, VIC Australia.
Alison C
AC
West
QIMR Berghofer Medical Research Institute; Herston, QLD Australia ; School of Medicine; University of Queensland; Herston, QLD Australia.
Mark J
MJ
Smyth
Cancer Therapeutics Program; The Peter MacCallum Cancer Centre; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; University of Melbourne; Parkville, VIC Australia.
Ricky W
RW
Johnstone
HDACi; anticancer immunity; anticancer therapy; epigenetic regulatory agent; immunogenic cell death; immunotherapy